Maja Pedersen, Chief Operating Officer, FUJIFILM Biotechnologies, a CDMO of biologic drug substances, advanced therapies, and drug products, provided an update of the company’s multi-year $8-billion expansion plan at the DCAT Member Company Announcement Forum, held March 23, 2026, at DCAT Week.

The company is advancing mammalian cell-culture manufacturing expansions at three sites. In Billingham Teesside, UK, a 212,200-ft² expansion for small- and mid-scale single-use manufacturing and process development opened in February 2026, with operations scheduled for the first half of 2026. This expansion brings 5,000-L single-use mid-scale capacity to complement existing small-scale single-use and large-scale stainless-steel assets. In Holly Springs, North Carolina, the company’s 1.5 million-ft² large-scale stainless-steel facility is coming online. Phase 1 opened in September 2025 with two large-scale drug-substance suites, and Phase 2 is on track to be completed in the second half of FY 2027. In Toyama, Japan, construction of a 16,000-m² site with small- and mid-scale single-use capacity was completed in December 2025 with future ability to manufacture antibody drug conjugates (ADCs). The site is anticipated to be operational in 2027.

The Billingham expansion also marks the company’s first kojoX facility in the UK (kojoX refers to a proprietary modular biomanufacturing system) and the first small- and mid-scale site in the company’s global kojoX ecosystem. The expanded UK operations will align with the company’s Toyama site (equipped with 2,000-L and 5,000-L bioreactors) and the company’s College Station, Texas, site (2,000 L). As demand grows, the company said it see opportunities to add small- and mid-scale mammalian drug substance capacity in the United States.

The company is also advancing drug-product and finished-goods expansions in three regions. In Hillerød, Denmark, the company completed a successful inspection by the Danish Medicines Agency of its Annex 1–compliant facility, which includes liquid vials, syringes, and cartridges, plus device assembly (e.g., autoinjector labeling and packaging). GMP drug product is expected to be online in the first half of 2026, with customers beginning initial tech transfers. In Holly Springs, North Carolina, the drug-product and finished-goods expansion is progressing, and drug product is expected online in 2026. In Toyama, Japan, ADC drug product capabilities for vial filling are under development, and the facility is scheduled to be operational in 2027.

To complement these capacity expansions, the company continues to advance its technology portfolio to support complex biologics and advanced therapies. It recently launched ShunzymeX, a proprietary precision purification technology to simplify downstream processing, which can be combined with the company’s Paveway PLUS and SymphonX technologies to accelerate development of complex biologics. Development of these and many more technologies are supported through collaboration between more than 400 process development scientists in its global network, Fujifilm’s innovation hub in Japan (the Bioscience & Engineering Laboratories – BSEL), and external partners.